People · Operator
Named in public records as an officer, director or promoter · active 2025–2025 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Antares Therapeutics, Inc. | — | Biotechnology | Series B | $70.0M | $149.7M | 2025 |
Menelas N. Pangalos at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Menelas N. Pangalos on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Jean-Francois Formela | 1 | 17 |
| Shelley Chu | 1 | 10 |
| Adam Friedman | 1 | 6 |
| Keith Flaherty | 1 | 5 |
| Jeffrey Albers | 1 | 3 |
| Andrew Fedder | 1 | 2 |
| Brian Piper | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.